New outpatient treatment trial offers hope for Tough-to-Treat lymphoma patients
NCT ID NCT06811272
Summary
This study is testing whether the drug epcoritamab can help control aggressive lymphoma that has returned or stopped responding to initial treatment. It's for patients who are not candidates for a stem cell transplant. Researchers will give the drug in an outpatient setting and measure how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Newton-Wellesley Hospital
RECRUITINGNewton, Massachusetts, 02462, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.